BIONTECH SE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.55 EUR | +0.54% |
|
-2.10% | -11.60% |
| 12:46pm | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
| 05-17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.8B 3.04B 4.14B | Sales 2025 * | 2.77B 3.01B 4.09B | Capitalization | 20.55B 22.32B 30.41B |
|---|---|---|---|---|---|
| Net income 2024 * | -415M -451M -614M | Net income 2025 * | -491M -534M -727M | EV / Sales 2024 * | 2.06 x |
| Net cash position 2024 * | 14.78B 16.05B 21.87B | Net cash position 2025 * | 13.76B 14.95B 20.37B | EV / Sales 2025 * | 2.45 x |
| P/E ratio 2024 * |
-49
x | P/E ratio 2025 * |
-43.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioNTech SE
More recommendations
More press releases
More news
| 1 week | -2.10% | ||
| Current month | +1.26% | ||
| 1 month | +2.56% | ||
| 3 months | -0.47% | ||
| 6 months | -6.82% | ||
| Current year | -11.60% |
1 week
83.05
86.05
1 month
80.1588.15
3 years
78.70397.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 08-06-01 |
Özlem Türeci
FOU | Founder | 57 | 08-06-01 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 69 | 21-12-31 |
| Director/Board Member | 67 | 08-06-01 | |
Helmut Jeggle
CHM | Chairman | 53 | 08-06-01 |
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 84.55 | +0.54% |
| 24-05-20 | 84.1 | +0.90% |
| 24-05-17 | 83.35 | -2.51% |
| 24-05-16 | 85.5 | +1.00% |
| 24-05-15 | 84.65 | -0.41% |
Real-time BOERSE MUENCHEN, May 21, 2024 at 08:00 am
More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
2024-08-04
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
85.14
EUR
Average target price
105.4
EUR
Spread / Average Target
+23.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.32% | 21.6B | |
| -6.36% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B | |
| -24.50% | 8.28B |
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock